Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Systemic Lupus Erythematosus (SLE) Clinical Trials

22 recruiting trials for Systemic Lupus Erythematosus (SLE). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
22
Total Trials
22
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients...

Sponsor: RenJi HospitalEnrolling: 301 location
RECRUITINGPhase 1NCT06978647

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 121 location
RECRUITINGPhase 2NCT05688696

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

This is a phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of orelabrutinib in adult subjects with SLE who are...

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.Enrolling: 18620 locations
RECRUITINGPhase 1NCT06799520

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171...

The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The...

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 306 locations
RECRUITINGEarly Phase 1NCT07339332

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection...

This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with...

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 121 location
RECRUITINGPhase 1NCT06980597

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.

Sponsor: Beijing GoBroad HospitalEnrolling: 442 locations
RECRUITINGPhase 2NCT07340463

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis...

1. Study Design This is a single-center, prospective, randomized, controlled, exploratory clinical trial. The study is designed to evaluate and compare the efficacy and safety of...

Sponsor: Nanjing University School of MedicineEnrolling: 501 location
RECRUITINGNCT06927219

Research Accelerated by You Lupus Registry

Summary The Lupus Foundation of America (LFA) Research Accelerated by You (RAY) Registry is a fully remote, longitudinal registry designed to collect data from adults and children...

Sponsor: Lupus Foundation of AmericaEnrolling: 100001 location
RECRUITINGPhase 1NCT07031713

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus...

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 121 location
RECRUITINGPhase 1NCT07104721

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 2NCT07447986

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in...

Sponsor: Hangzhou Sumgen Biotech Co., Ltd.Enrolling: 1201 location
RECRUITINGEarly Phase 1NCT07174843

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

This is a single arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of autologous chimeric antigen receptor T...

Sponsor: Shanghai Cell Therapy Group Co.,LtdEnrolling: 201 location
RECRUITINGPhase 1NCT06892145

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 122 locations
RECRUITINGNCT07425730

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

To investigate biomarkers to identify pediatric SR-SLE patients by non-invasive echocardiographic techniques.

Sponsor: Shanghai Jiao Tong University School of MedicineEnrolling: 601 location
RECRUITINGPhase 1NCT07123519

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 1NCT06737380

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to...

Sponsor: LiveKidney.BioEnrolling: 101 location
RECRUITINGPhase 3NCT04702256

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus...

This is a randomised, open label, controlled non-inferiority phase III multicentre trial. As primary objective, the study aims to demonstrate that a regimen free of additional...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1961 location
RECRUITINGNCT06902844

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed...

Sponsor: Tongji HospitalEnrolling: 61 location
RECRUITINGPhase 1NCT07085676

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART...

Sponsor: Polina StepenskyEnrolling: 601 location
RECRUITINGEarly Phase 1NCT06888960

Safety Study of CC312 in Autoimmune Disease Patients

This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult...

Sponsor: CytoCares IncEnrolling: 181 location
RECRUITINGPhase 1NCT06308978

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product...

Sponsor: Fate TherapeuticsEnrolling: 24417 locations
RECRUITINGEarly Phase 1NCT07490041

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of...

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic...

Sponsor: The Children's Hospital of Zhejiang University School of MedicineEnrolling: 361 location